Clinical Trial Update: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether metformin can prevent progression from precursor conditions to active multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Smoldering Multiple Myeloma

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-09